OptiBiotix Health plc (LON:OPTI) has announced it has entered into an evaluation agreement with a global dairy company for its SweetBiotix calorie-free sweet fibres.
The AIM-listed company said the agreement grants a non-exclusive licence for an evaluation period to explore the potential for using the SweetBiotix technology to reduce the sugar content in a range of its dairy food products.
READ: OptiBiotix Health raises £1.5mln in oversubscribed placing to capitalise on opportunities
OptiBiotix revealed that the undisclosed company is a global brand and one of the world’s largest providers of dairy products with an annual turnover exceeding US$10bn.
The company, which is developing compounds to tackle obesity, high cholesterol and diabetes, has previously announced that the five successful human taste studies on the SweetBiotix product development had created interest from several companies.
OPtiBiotix said this agreement reflects interest from one of these companies in exploring the use of SweetBiotix in its branded dairy products.
Stephen O’Hara, CEO of the company, said: “This is part of a strategy of working with global partners who have the capability and expertise to manufacture speciality ingredients like SweetBiotix and well-known consumer brands who have the specialist application expertise to incorporate this technology in to their own branded breaded, dairy, cereal and beverage consumer products.”
He added: “This approach provides a low-risk way to fully exploit the wide range of opportunities offered by our SweetBiotix technology.”